medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2018, Número S1

<< Anterior Siguiente >>

Acta Med 2018; 16 (S1)


El tratamiento de la hiperuricemia en la enfermedad renal crónica

Ramírez SJC, Madero RM

Idioma: Español
Referencias bibliográficas: 45
Paginas: 53-59
Archivo PDF: 152.01 Kb.


RESUMEN

La hiperuricemia puede ser un importante contribuyente al desarrollo o progresión de la enfermedad renal crónica. Aunque no existe un punto de corte claro en donde el ácido úrico (AU) se asocie a riesgo de daño renal, éste parece incrementar conforme a los niveles de AU. En pacientes con hiperuricemia se recomiendan intervenciones de estilo de vida tales como ejercicio, reducción de peso, bajo consumo de carne rica en purinas o evitar la ingesta alta de fructosa. Los fármacos para reducción de urato como el alopurinol o el febuxostat pueden ser una opción como un agente renoprotector, pero los ensayos clínicos aleatorios que evalúan la seguridad y eficacia de estos fármacos se limitan a un pequeño número de estudios de un solo centro. Varios ensayos clínicos en curso tienen como objetivo evaluar la seguridad y la eficacia de estos medicamentos. Al día de hoy, no hay pruebas suficientes para recomendar el uso generalizado de fármacos para reducir el AU con la finalidad de prevenir o retrasar la progresión de la enfermedad renal crónica (ERC). El objetivo de esta revisión es resumir la evidencia y la perspectiva futura sobre el tratamiento de la hiperuricemia en la prevención y progresión de la enfermedad renal crónica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009; 53 (5): 796-803.

  2. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: Which is chasing which? Nephrol Dial Transplant. 2013; 28 (9): 2221-2228.

  3. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 1999; 33 (2): 225-234.

  4. Eleftheriadis T, Golphinopoulos S, Pissas G, Stefanidis I. Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial. J Adv Res. 2017; 8 (5): 555-560.

  5. Kumagai T, Ota T, Tamura Y, Chang WX, Shibata S, Uchida S. Time to target uric acid to retard CKD progression. Clin Exp Nephrol. 2017; 21 (2): 182-192.

  6. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015; 33 (9): 1729-141.

  7. Chen JH, Yeh WT, Chuang SY, Wu YY, Pan WH. Gender-specific risk factors for incident gout: a prospective cohort study. Clin Rheumatol. 2012; 31 (2): 239-245.

  8. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972; 15 (2): 189-192.

  9. Yamanaka H; Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011; 30 (12): 1018-1029.

  10. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011; 63 (1): 102-110.

  11. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014; 29 (2): 406-413.

  12. Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013; 125 (1): 106-114.

  13. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic non pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64 (10): 1431-1446.

  14. Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010; 22 (2): 165-172.

  15. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000; 59 (7): 539-543.

  16. Lim JH, Kim YK, Kim YS, Na SH, Rhee MY, Lee MM. Relationship between serum uric acid levels, metabolic syndrome, and arterial stiffness in Korean. Korean Circ J. 2010; 40 (7): 314-320.

  17. Johnson RJ, Sautin YY, Oliver WJ, Roncal C, Mu W, Gabriela Sanchez-Lozada L et al. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in Western society? J Comp Physiol B. 2009; 179 (1): 67-76.

  18. Madero M, Rodriguez-Castellanos FE, Jalal D, Villalobos-Martin M, Salazar J, Vazquez-Rangel A et al. A pilot study on the impact of a low fructose diet and allopurinol on clinic blood pressure among overweight and prehypertensive subjects: a randomized placebo controlled trial. J Am Soc Hypertens. 2015; 9 (11): 837-44.

  19. Zhao CC, Wang AP, Li LX, Li TT, Chen MY, Zhu Y et al. Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabetes Complications. 2016; 30 (6): 1074-1080.

  20. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65 (10): 1312-1324.

  21. Dalbeth N, Stamp LK. Gout: Why compare the effectiveness of suboptimal gout management? Nat Rev Rheumatol. 2015; 11 (9): 506-507.

  22. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005; 76 (16): 1835-1847.

  23. Grabowski BA, Khosravan R, Vernillet L, Mulford DJ. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J Clin Pharmacol. 2011; 51 (2): 189-201.

  24. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12 (2): R63.

  25. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010; 5 (8): 1388-1393.

  26. Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C et al. Uric acid in metabolic syndrome: From an innocent bystander to a central player. Eur J Intern Med. 2016; 29: 3-8.

  27. Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011; 22 (7): 1382-1389.

  28. Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012; 35 (3): 153-160.

  29. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015; 16 (1): 58.

  30. Talaat KM, El-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007; 27 (5): 435-440.

  31. Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015; 67 (4): 588-592.

  32. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011; 17 (1): 7-13.

  33. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015; 66 (6): 945-950.

  34. Sánchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008; 295 (4): F1134-F1141.

  35. Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009; 48 (2): 188-194.

  36. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014; 18 (6): 876-884.

  37. Fujimori S, Ooyama K, Ooyama H, Moromizato H. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. Nucleosides Nucleotides Nucleic Acids. 2011; 30 (12): 1035-1038.

  38. Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011; 58 (1): 2-7.

  39. Van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 2017; 12 (4): 700-710.

  40. Huang HY, Appel LJ, Choi MJ, Gelber AC, Charleston J, Norkus EP et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum. 2005; 52 (6): 1843-1847.

  41. National Research Infrastructure for Australia. Trial review - ANZCTR. 2016. Disponible en: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12613000513718

  42. Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials. 2014; 15: 26.

  43. Maahs DM, Caramori L, Cherney DZI, Galecki AT, Gao C, Jalal D et al. Uric acid lowering to prevent kidney function loss in diabetes: the Preventing Early Renal Function Loss (PERL) allopurinol study. Curr Diab Rep. 2013; 13 (4): 550-559.

  44. Ling Wang. Compare the renal protective effects of febuxostat and benzbromarone —Tabular view— ClinicalTrials.gov [Internet]. [cited 2017 Jul 29]. Disponible en: https://clinicaltrials.gov/ct2/show/record/NCT02338323?term=febuxostat&recrs=a&rank=3

  45. AstraZeneca. Intensive uric acid lowering with RDEA3170 and febuxostat in patients with albuminuria —Tabular view— ClinicalTrials.gov [Internet]. [Cited 2017 Jul 29]. Disponible en: https://clinicaltrials.gov/ct2/show/record/NCT03118739?term=febuxostat&recrs=a&rank=4




2020     |     www.medigraphic.com